课题基金 / 基金详情

Development of a novel vaccine platform: Surface Antigen/Adjuvant Vaccine Engineering (SAAVE)

Development of a novel vaccine platform: Surface Antigen/Adjuvant Vaccine Engineering (SAAVE)
新型疫苗平台的开发:表面抗原/佐剂疫苗工程(SAAVE)
批准号:
9899172
负责人:
Michael Stephen Trent
金额:
$74.97万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-05-22 至 2022-04-30

项目摘要

项目成果

Michael Stephen Trent的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Abstract Vaccination is perhaps the most effective public health intervention in the history of mankind. Over the past 200 years, there have been many accomplishments in vaccine development with successes against diseases such as smallpox, polio, tetanus, diphtheria, and others. However, there is an ever-growing need for new vaccine technologies to combat diseases that are difficult to target. Furthermore, vaccination may be the only course of action to prevent infectious diseases caused by multi-drug resistant pathogens. The primary objective of the current application is to develop a vaccine platform that allows for the display of both engineered antigens and adjuvants on the surface of non-pathogenic E. coli. This platform permits the use of whole bacteria and outer membrane vesicles (OMVs) as both vaccine production and vaccine delivery systems. In the current application, this innovative, efficient, and cost-effective vaccine platform will be directly applied to the production of a broadly protective, universal influenza vaccine. Seasonal influenza epidemics cause millions of cases of severe infection per year worldwide and an uncontrolled influenza pandemic could result in the death of tens of millions. The most effective approach to protecting the population from influenza is through vaccination; however, current influenza vaccines are not broadly protective and must be updated yearly in an inefficient, expensive, and laborious process. Our new antigen/adjuvant bacterial display platform has the potential to overcome these weaknesses. The Specific Aims of this proposal are (i) to engineer the bacterial surface of E. coli for display of targeted antigens and adjuvants for protective vaccines, (ii) to engineer the production of polyvalent influenza vaccine offering heterosubtypic immunity, and (iii) to test the efficacy and durability of protection induced by our engineered universal influenza vaccines in ferrets.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The role of cardiolipin in the biogenesis of the Gram-negative bacterial cell envelope
  • 批准号:
    10731444
  • 项目类别:
  • 资助金额:
    $67.71万
  • 财政年份:
    2023
  • 负责人:
    Michael Stephen Trent
  • 依托单位:
Synthesis and transport of outer membrane components across the Gram-negative cell envelope
  • 批准号:
    10680968
  • 项目类别:
  • 资助金额:
    $57.98万
  • 财政年份:
    2023
  • 负责人:
    Michael Stephen Trent
  • 依托单位:
2022 Bacterial Cell Surfaces GRC/GRS
  • 批准号:
    10374358
  • 项目类别:
  • 资助金额:
    $0.5万
  • 财政年份:
    2022
  • 负责人:
    Michael Stephen Trent
  • 依托单位:
The Cell Envelope of the Multi-Drug Resistant Pathogen Acinetobacter baumannii
  • 批准号:
    10113527
  • 项目类别:
  • 资助金额:
    $53.93万
  • 财政年份:
    2020
  • 负责人:
    Michael Stephen Trent
  • 依托单位:
海外基金